Miedzo Yekiriniki YeCAR T-Cell Therapy MuChina Yakaratidza Kubudirira Kunoshamisa
2024 yanga iri shanduko-yemutambo weCAR T-Cell kurapwa muChina! Pupurira nyaya dzebudiriro dzinoshamisa kubva kuzviyedzo zvekiriniki, ongorora kufambira mberi, uye dzidza nezvematambudziko asara. Huya uone ramangwana reiyi ground-breaki..
Kunyatsotarisisa Kwenguva Ichangoburwa YeCancer Clinical Miedzo muChina Uye Mushonga Mutsva Wegomarara Wakabvumidzwa
Chinyorwa ichi chinonyatso ongorora kenza yemakiriniki miedzo muChina mumakore mashoma apfuura, ichitarisa pane zvakakura zvakawanikwa nenzvimbo dzekufambira mberi. Inokurukura zvakare mishonga yegomarara ichangobva kubvumidzwa muChina, ichiongorora maitiro avo, e..
CAR T Cell therapy miedzo, Glioblastoma, glioblastoma miedzo, gliomas
Kuchengeteka uye Kubudirira Kudzidza kweAnti-B7-H3 CAR-T Cell Therapy yeRecurrent Glioblastoma
Kurume 2023: Rudzi rweChidzidzo : Yekupindira (Kuyedzwa Kwekiriniki) Hunofungidzirwa Kunyoresa : 30 vatori vechikamuKugoverwa: N/AIKupindira Muenzanisi: Inotevedzana AssignmentIntervention Model Tsananguro: "3+3" dhizaini inoshandiswa kuona Maximum.
bhora, Bhora Miedzo, CAR T Cell therapy miedzo, Clinical trials, Leukemia, Leukemia miedzo, Miedzo muChina
Kliniki yekuyedza kunyorera Bhora CAR T-Cell kurapwa
16 Kurume 2023: Kurapwa kwegomarara kuri kuvandudzwa nemishonga mitsva yeimmunotherapeutic inonangana neiyo microenvironment panzvimbo yebundu. T masero ane chimeric antigen receptors (CAR) ari kuongororwa zvakanyanya.